News coverage about Edwards Lifesciences Corporation (NYSE:EW) has been trending positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences Corporation earned a news sentiment score of 0.39 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 56 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- CVS Health (CVS) Q2 Earnings Beat, ’17 Guidance Narrowed – Nasdaq (nasdaq.com)
- Edwards Lifesciences Corporation (EW) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Insider Selling: Edwards Lifesciences Corporation (EW) VP Sells 25,000 Shares of Stock (americanbankingnews.com)
- Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss (finance.yahoo.com)
- Evolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top (finance.yahoo.com)
Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 116.16 on Wednesday. The firm’s 50-day moving average price is $117.28 and its 200 day moving average price is $104.65. The company has a market capitalization of $24.53 billion, a PE ratio of 35.23 and a beta of 0.63. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. During the same period last year, the firm posted $0.76 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. Analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.
A number of equities research analysts have weighed in on EW shares. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday, April 26th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday, April 26th. Jefferies Group LLC restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Vetr downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating and set a $110.88 target price on the stock. in a research note on Wednesday, April 26th. Finally, Goldman Sachs Group, Inc. (The) started coverage on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences Corporation has a consensus rating of “Buy” and a consensus price target of $121.13.
WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/edwards-lifesciences-corporation-nyseew-receives-daily-news-sentiment-score-of-0-39-updated-updated-updated/1197753.html.
In other news, VP Patrick B. Verguet sold 22,631 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $113.16, for a total transaction of $2,560,923.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total value of $3,883,845.00. The disclosure for this sale can be found here. Insiders have sold 150,512 shares of company stock valued at $17,360,159 over the last 90 days. 2.13% of the stock is owned by corporate insiders.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with our FREE daily email newsletter.